NCT03182725View on ClinicalTrials.gov

Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

May 8, 2020

Study Completion Date

May 8, 2020

Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
DRUG

Ivabradine

Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.

DRUG

Placebo

A substance that has no therapeutic effect and will act as a control.

Trial Locations (1)

92093

University of California, San Diego, La Jolla

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

University of California, San Diego

OTHER